The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

In the present double blind, placebo-controlled, parallel study we evaluated the impact of 12 weeks thiazolidinedione (TZD) administration on basal and insulin-stimulated substrate metabolism in growth hormone-replaced adults with growth hormone deficiency.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Treatments: Hormones; Insulin; Pioglitazone

Criteria

Inclusion Criteria:

• Growth hormone replaced (minimum 6 months) growth hormone deficient men

• Age over 18 years

Exclusion Criteria:

• Ischemic coronary disease, defined by EF<0.6, former myocardial infarction, angina pectoris or actual treatment of cardiac insufficiency

• Actual or former malignancy, except intracranial neoplasia that caused the participants pituitary disease, provided that there was clinical evidence for permanent remission

• Blood donation within 6 months

• Excessive alcohol consumption

• Known allergic reaction from contents of test drug

• Radioactive radiation exposure in terms of treatment or study enrollment within one year

• Liver insufficiency

• Insulin treatment